228 related articles for article (PubMed ID: 23679684)
1. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Abrahão AC; Giudice FS; Sperandio FF; Pinto Junior Ddos S
J Oral Pathol Med; 2013 Nov; 42(10):793-8. PubMed ID: 23679684
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.
Park SW; Kim HS; Hah JW; Jeong WJ; Kim KH; Sung MW
Anticancer Drugs; 2010 Oct; 21(9):823-30. PubMed ID: 20717005
[TBL] [Abstract][Full Text] [Related]
3. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
5. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
6. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
Kim N; Kim CH; Ahn DW; Lee KS; Cho SJ; Park JH; Lee MK; Kim JS; Jung HC; Song IS
J Gastroenterol Hepatol; 2009 Mar; 24(3):480-7. PubMed ID: 18823436
[TBL] [Abstract][Full Text] [Related]
7. Endoplasmic reticulum stress response as a possible mechanism of cyclooxygenase-2-independent anticancer effect of celecoxib.
Cha W; Park SW; Kwon TK; Hah JH; Sung MW
Anticancer Res; 2014 Apr; 34(4):1731-5. PubMed ID: 24692703
[TBL] [Abstract][Full Text] [Related]
8. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Zhao Y; Hao Y; Ji H; Fang Y; Guo Y; Sha W; Zhou Y; Pang X; Southerland WM; Califano JA; Gu X
Cancer Prev Res (Phila); 2010 Jun; 3(6):787-96. PubMed ID: 20501859
[TBL] [Abstract][Full Text] [Related]
9. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B; Shi ZL; Feng J; Tao HM
Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
12. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells.
Jeon YW; Suh YJ
Oncol Rep; 2013 Feb; 29(2):819-25. PubMed ID: 23229294
[TBL] [Abstract][Full Text] [Related]
13. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
14. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.
Kwak YE; Jeon NK; Kim J; Lee EJ
Ann N Y Acad Sci; 2007 Jan; 1095():99-112. PubMed ID: 17404023
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib toxicity is cell cycle phase specific.
Bock JM; Menon SG; Sinclair LL; Bedford NS; Goswami PC; Domann FE; Trask DK
Cancer Res; 2007 Apr; 67(8):3801-8. PubMed ID: 17440094
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
Barnes NL; Warnberg F; Farnie G; White D; Jiang W; Anderson E; Bundred NJ
Br J Cancer; 2007 Feb; 96(4):575-82. PubMed ID: 17285134
[TBL] [Abstract][Full Text] [Related]
17. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
[TBL] [Abstract][Full Text] [Related]
18. Anticancer effects of celecoxib through inhibiton of STAT3 phosphorylation and AKT phosphorylation in nasopharyngeal carcinoma cell lines.
Liu DB; Long GX; Mei Q; Wang JF; Hu GY; Gan L; Li WW; Sun W; Liu SF; Jiang JZ; Hu GQ
Pharmazie; 2014 May; 69(5):358-61. PubMed ID: 24855827
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Sui W; Zhang Y; Wang Z; Wang Z; Jia Q; Wu L; Zhang W
Oncol Rep; 2014 May; 31(5):2252-60. PubMed ID: 24647425
[TBL] [Abstract][Full Text] [Related]
20. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
